Early Alzheimer's Disease Clinical Trial
Official title:
Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Over 18 Months.
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo for approximately 18 months (72 weeks) in approximately 540 participants diagnosed with early Alzheimer's disease Participants will be randomized 1:1:1 to receive either 100mg or 200mg of CT1812 or placebo. CT1812 or placebo will be administered as 2 capsules to be taken orally once daily. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04693520 -
Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
|
Phase 2 | |
| Recruiting |
NCT05122598 -
Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease
|
Phase 2 | |
| Active, not recruiting |
NCT04770220 -
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
|
Phase 3 | |
| Active, not recruiting |
NCT04777396 -
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
|
Phase 3 | |
| Active, not recruiting |
NCT03887455 -
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
|
Phase 3 | |
| Recruiting |
NCT04599764 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease
|
N/A | |
| Completed |
NCT05161715 -
Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
|
Phase 2 | |
| Completed |
NCT02859207 -
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
|
Phase 1 | |
| Enrolling by invitation |
NCT06304883 -
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
|
Phase 3 |